Search

Your search keyword '"Garralda, Elena"' showing total 672 results
Start Over Author "Garralda, Elena"
672 results on '"Garralda, Elena"'

1. Generation of chimeric antigen receptor T cells targeting p95HER2 in solid tumors

Author

Román Alonso, Macarena, Grinyó-Escuer, Ariadna, Duro-Sánchez, Santiago, Rius-Ruiz, Irene, Bort-Brusca, Marta, Escorihuela, Marta, Maqueda-Marcos, Susana, Pérez-Ramos, Sandra, Gago, Judit, Nogales, Vanesa, Espinosa-Bravo, Martín, Peg, Vicente, Escrivá-de-Romaní, Santiago, Foradada, Laia, Soucek, Laura, Braña, Irene, Galvao, Vladimir, Martín-Lluesma, Silvia, Moessner, Ekkehard, Klein, Christian, Garralda, Elena, Saura, Cristina, and Arribas, Joaquín

Published
2024
Full Text
View/download PDF

2. Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer: Alexandra Leary

Author

Leary, Alexandra, Estévez-García, Purificación, Sabatier, Renaud, Ray-Coquard, Isabelle, Romeo, Margarita, Barretina-Ginesta, Pilar, Gil-Martin, Marta, Garralda, Elena, Bosch-Barrera, Joaquim, Morán, Teresa, Martin-Martorell, Paloma, Nadal, Ernest, Gascón, Pere, Rodon, Jordi, Lizcano, Jose M, Muñoz-Guardiola, Pau, Fierro-Durán, Gemma, Pedrós-Gámez, Oriol, Pérez-Montoyo, Héctor, Yeste-Velasco, Marc, Cortal, Marc, Pérez-Campos, Antonio, Alfon, Jose, Domenech, Carles, Pérez-Fidalgo, Alejandro, and Oaknin, Ana

Published
2024
Full Text
View/download PDF

3. ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer

Author

Leary, Alexandra, Estévez-García, Purificación, Sabatier, Renaud, Ray-Coquard, Isabelle, Romeo, Margarita, Barretina-Ginesta, Pilar, Gil-Martin, Marta, Garralda, Elena, Bosch-Barrera, Joaquim, Morán, Teresa, Martin-Martorell, Paloma, Nadal, Ernest, Gascón, Pere, Rodon, Jordi, Lizcano, Jose M, Muñoz-Guardiola, Pau, Fierro-Durán, Gemma, Pedrós-Gámez, Oriol, Pérez-Montoyo, Héctor, Yeste-Velasco, Marc, Cortal, Marc, Pérez-Campos, Antonio, Alfon, Jose, Domenech, Carles, Pérez-Fidalgo, Alejandro, and Oaknin, Ana

Published
2024
Full Text
View/download PDF

5. Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumors

Author

Geva, Ravit, Vieito, Maria, Ramon, Jorge, Perets, Ruth, Pedregal, Manuel, Corral, Elena, Doger, Bernard, Calvo, Emiliano, Bardina, Jorge, Garralda, Elena, Brown, Regina J., Greger, James G., Wu, Shujian, Steinbach, Douglas, Yao, Tsun-Wen Sheena, Cao, Yu, Lauring, Josh, Chaudhary, Ruchi, Patel, Jaymala, Patel, Bharvin, and Moreno, Victor

Published
2024
Full Text
View/download PDF

6. MYC targeting by OMO-103 in solid tumors: a phase 1 trial

Author

Garralda, Elena, Beaulieu, Marie-Eve, Moreno, Víctor, Casacuberta-Serra, Sílvia, Martínez-Martín, Sandra, Foradada, Laia, Alonso, Guzman, Massó-Vallés, Daniel, López-Estévez, Sergio, Jauset, Toni, Corral de la Fuente, Elena, Doger, Bernard, Hernández, Tatiana, Perez-Lopez, Raquel, Arqués, Oriol, Castillo Cano, Virginia, Morales, Josefa, Whitfield, Jonathan R., Niewel, Manuela, Soucek, Laura, and Calvo, Emiliano

Published
2024
Full Text
View/download PDF

7. Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool): a prospective observational study

Author

Mirallas, Oriol, Martin-Cullell, Berta, Navarro, Víctor, Vega, Kreina Sharela, Recuero-Borau, Jordi, Gómez-Puerto, Diego, López-Valbuena, Daniel, Salva de Torres, Clara, Andurell, Laura, Pedrola, Anna, Berché, Roger, Palmas, Fiorella, Ucha, José María, Villacampa, Guillermo, Rezqallah, Alejandra, Sanz-Beltran, Judit, Bach, Rafael, Bueno, Sergio, Viaplana, Cristina, Molina, Gaspar, Hernando-Calvo, Alberto, Aguilar-Company, Juan, Roca, María, Muñoz-Couselo, Eva, Martínez-Martí, Alex, Alonso, Ada, Eremiev, Simeon, Macarulla, Teresa, Oaknin, Ana, Saura, Cristina, Élez, Elena, Felip, Enriqueta, Peñuelas, Ángeles, Burgos, Rosa, Pardo, Patricia Gómez, Garralda, Elena, Tabernero, Josep, Serradell, Sònia, Servitja, Sònia, Paez, David, Dienstmann, Rodrigo, and Carles, Joan

Published
2024
Full Text
View/download PDF

9. Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab

Author

Hernando-Calvo, Alberto, Yang, S.Y. Cindy, Vila-Casadesús, Maria, Han, Ming, Liu, Zhihui Amy, Berman, A Hal K., Spreafico, Anna, Razak, Albiruni Abdul, Lheureux, Stephanie, Hansen, Aaron R., Lo Giacco, Deborah, Abbas-Aghababazadeh, Farnoosh, Matito, Judith, Haibe-Kains, Benjamin, Pugh, Trevor J., Bratman, Scott V., Aleshin, Alexey, Berche, Roger, Saavedra, Omar, Garralda, Elena, Elston, Sawako, Siu, Lillian L., Ohashi, Pamela S., Vivancos, Ana, and Bedard, Philippe L.

Published
2024
Full Text
View/download PDF

11. Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group

Author

Nakajima, Erica C., Simpson, Amber, Bogaerts, Jan, de Vries, Elisabeth G.E., Do, Richard, Garralda, Elena, Goldmacher, Greg, Kinahan, Paul E., Lambin, Philippe, LeStage, Barbara, Li, Qin, Lin, Frank, Litière, Saskia, Perez-Lopez, Raquel, Petrick, Nicholas, Schwartz, Lawrence, Seymour, Lesley, Shankar, Lalitha, and Laurie, Scott A.

Published
2024
Full Text
View/download PDF

14. A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials

Author

Hernando-Calvo, Alberto, Vila-Casadesús, Maria, Bareche, Yacine, Gonzalez-Medina, Alberto, Abbas-Aghababazadeh, Farnoosh, Lo Giacco, Deborah, Martin, Agatha, Saavedra, Omar, Brana, Irene, Vieito, Maria, Fasani, Roberta, Stagg, John, Mancuso, Francesco, Haibe-Kains, Benjamin, Han, Ming, Berche, Roger, Pugh, Trevor J., Mirallas, Oriol, Jimenez, Jose, Gonzalez, Nadia Saoudi, Valverde, Claudia, Muñoz-Couselo, Eva, Suarez, Cristina, Diez, Marc, Élez, Elena, Capdevila, Jaume, Oaknin, Ana, Saura, Cristina, Macarulla, Teresa, Galceran, Joan Carles, Felip, Enriqueta, Dienstmann, Rodrigo, Bedard, Philippe L., Nuciforo, Paolo, Seoane, Joan, Tabernero, Josep, Garralda, Elena, and Vivancos, Ana

Published
2023
Full Text
View/download PDF

15. Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

Author

Drilon, Alexander, Oxnard, Geoffrey R, Tan, Daniel SW, Loong, Herbert HF, Johnson, Melissa, Gainor, Justin, McCoach, Caroline E, Gautschi, Oliver, Besse, Benjamin, Cho, Byoung C, Peled, Nir, Weiss, Jared, Kim, Yu-Jung, Ohe, Yuichiro, Nishio, Makoto, Park, Keunchil, Patel, Jyoti, Seto, Takashi, Sakamoto, Tomohiro, Rosen, Ezra, Shah, Manisha H, Barlesi, Fabrice, Cassier, Philippe A, Bazhenova, Lyudmila, De Braud, Filippo, Garralda, Elena, Velcheti, Vamsidhar, Satouchi, Miyako, Ohashi, Kadoaki, Pennell, Nathan A, Reckamp, Karen L, Dy, Grace K, Wolf, Jürgen, Solomon, Benjamin, Falchook, Gerald, Ebata, Kevin, Nguyen, Michele, Nair, Binoj, Zhu, Edward Y, Yang, Luxi, Huang, Xin, Olek, Elizabeth, Rothenberg, S Michael, Goto, Koichi, and Subbiah, Vivek

Subjects
Lung Cancer, Clinical Research, Lung, Cancer, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Female, Humans, Hypertension, Intention to Treat Analysis, Lung Neoplasms, Male, Middle Aged, Mutation, Progression-Free Survival, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-ret, Pyrazoles, Pyridines, Transaminases, Treatment Outcome, Young Adult, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundRET fusions are oncogenic drivers in 1 to 2% of non-small-cell lung cancers (NSCLCs). In patients with RET fusion-positive NSCLC, the efficacy and safety of selective RET inhibition are unknown.MethodsWe enrolled patients with advanced RET fusion-positive NSCLC who had previously received platinum-based chemotherapy and those who were previously untreated separately in a phase 1-2 trial of selpercatinib. The primary end point was an objective response (a complete or partial response) as determined by an independent review committee. Secondary end points included the duration of response, progression-free survival, and safety.ResultsIn the first 105 consecutively enrolled patients with RET fusion-positive NSCLC who had previously received at least platinum-based chemotherapy, the percentage with an objective response was 64% (95% confidence interval [CI], 54 to 73). The median duration of response was 17.5 months (95% CI, 12.0 to could not be evaluated), and 63% of the responses were ongoing at a median follow-up of 12.1 months. Among 39 previously untreated patients, the percentage with an objective response was 85% (95% CI, 70 to 94), and 90% of the responses were ongoing at 6 months. Among 11 patients with measurable central nervous system metastasis at enrollment, the percentage with an objective intracranial response was 91% (95% CI, 59 to 100). The most common adverse events of grade 3 or higher were hypertension (in 14% of the patients), an increased alanine aminotransferase level (in 12%), an increased aspartate aminotransferase level (in 10%), hyponatremia (in 6%), and lymphopenia (in 6%). A total of 12 of 531 patients (2%) discontinued selpercatinib because of a drug-related adverse event.ConclusionsSelpercatinib had durable efficacy, including intracranial activity, with mainly low-grade toxic effects in patients with RET fusion-positive NSCLC who had previously received platinum-based chemotherapy and those who were previously untreated. (Funded by Loxo Oncology and others; LIBRETTO-001 ClinicalTrials.gov number, NCT03157128.).

Published
2020

16. Nutritional status associates with immunotherapy clinical outcomes in recurrent or metastatic head and neck squamous cell carcinoma patients

Author

Hernando-Calvo, Alberto, Mirallas, Oriol, Marmolejo, David, Saavedra, Omar, Vieito, María, Assaf Pastrana, Juan David, Aguilar, Susana, Bescós, Coro, Lorente, Juan, Giralt, Jordi, Benavente, Sergi, Temprana-Salvador, Jordi, Alberola, Margarita, Dienstmann, Rodrigo, Garralda, Elena, Felip, Enriqueta, Villacampa, Guillermo, and Brana, Irene

Published
2023
Full Text
View/download PDF

17. Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Author

Subbiah, Vivek, Cassier, Philippe A., Siena, Salvatore, Garralda, Elena, Paz-Ares, Luis, Garrido, Pilar, Nadal, Ernest, Vuky, Jacqueline, Lopes, Gilberto, Kalemkerian, Gregory P., Bowles, Daniel W., Seetharam, Mahesh, Chang, Jianhua, Zhang, Hui, Green, Jennifer, Zalutskaya, Alena, Schuler, Martin, Fan, Yun, and Curigliano, Giuseppe

Published
2022
Full Text
View/download PDF

18. Delivering precision oncology to patients with cancer

Author

Mateo, Joaquin, Steuten, Lotte, Aftimos, Philippe, André, Fabrice, Davies, Mark, Garralda, Elena, Geissler, Jan, Husereau, Don, Martinez-Lopez, Iciar, Normanno, Nicola, Reis-Filho, Jorge S., Stefani, Stephen, Thomas, David M., Westphalen, C. Benedikt, and Voest, Emile

Published
2022
Full Text
View/download PDF

19. A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.

Author

Lin, Chia-Chi, Garralda, Elena, Schöffski, Patrick, Hong, David S., Siu, Lillian L., Martin, Miguel, Maur, Michela, Hui, Rina, Soo, Ross A, Chiu, Joanne, Zhang, Tian, Ma, Brigette, Kyi, Chrisann, Tan, Daniel SW, Cassier, Philippe A., Sarantopoulos, John, Weickhardt, Andrew, Carvajal, Richard D., Spratlin, Jennifer, and Esaki, Taito

Abstract

Ieramilimab, a humanized anti-LAG-3 monoclonal antibody, was well tolerated in combination with the anti-PD-1 antibody spartalizumab in a phase 1 study. This phase 2 study aimed to further investigate the efficacy and safety of combination treatment in patients with selected advanced (locally advanced or metastatic) solid malignancies. Eligible patients with non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC), mesothelioma, and triple-negative breast cancer (TNBC) were grouped depending on prior anti-PD-1/L1 therapy (anti-PD-1/L1 naive or anti-PD-1/L1 pretreated). Patients received ieramilimab (400 mg) followed by spartalizumab (300 mg) every 3 weeks. The primary endpoint was objective response rate (ORR), along with safety, pharmacokinetics, and biomarker assessments. Of 235 patients, 142 were naive to anti-PD-1/L1 and 93 were pretreated with anti-PD-1/L1 antibodies. Durable responses (>24 months) were seen across all indications for patients naive to anti-PD-1/L1 and in melanoma and RCC patients pretreated with anti-PD1/L1. The most frequent study drug-related AEs were pruritus (15.5%), fatigue (10.6%), and rash (10.6%) in patients naive to anti-PD-1/L1 and fatigue (18.3%), rash (14.0%), and nausea (10.8%) in anti-PD-1/L1 pretreated patients. Biomarker assessment indicated higher expression of T-cell-inflamed gene signature at baseline among responding patients. Response to treatment was durable (>24 months) in some patients across all enrolled indications, and safety findings were in accordance with previous and current studies exploring LAG-3/PD-1 blockade. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Clinical protocol phase II study of tumor infiltrating lymphocytes in advanced tumors with alterations in the SWI/SNF complex: the TILTS study.

Author

Martin-Liberal, Juan, Garralda, Elena, García-Donas, Jesús, Soto-Castillo, Juan José, Mussetti, Alberto, Codony, Carles, Martin-Lluesma, Silvia, Muñoz, Susana, Galvao, Vladimir, Lostes, Julia, Rotxes, Marta, Prat-Vidal, Cristina, Palomero, Jara, Muñoz, Ainhoa, Moreno, Rafael, García del Muro, Xavier, Sureda, Anna, Alemany, Ramon, Gros, Alena, and Piulats, Josep Maria

Abstract

The SWI/SNF complex is a chromatin remodeling complex comprised by several proteins such as SMARCA4 or SMARCB1. Mutations in its components can lead to the development of aggressive rhabdoid tumors such as epithelioid sarcoma, malignant rhabdoid tumor or small cell carcinoma of the ovary hypercalcemic type, among others. These malignancies tend to affect young patients and their prognosis is poor given the lack of effective treatments. Characteristically, these tumors are highly infiltrated by TILs, suggesting that some lymphocytes are recognizing tumor antigens. The use of those TILs as a therapeutic strategy is a promising approach worth exploring. Here, we report the clinical protocol of the TILTS study, a Phase II clinical trial assessing personalized adoptive cell therapy with TILs in patients affected by these tumor types. Clinical Trial Registration: 2023-504632-17-00 (www.clinicaltrialsregister.eu) (ClinicalTrials.gov). Article highlights Background & rationale There is a group of tumors associated with alterations in the SWI/SNF complex, such as epithelioid sarcoma, malignant rhabdoid tumor or small cell carcinoma of the ovary hypercalcemic type, among others. These tumors usually have rhabdoid features and tend to affect young patients. Patients affected by these malignancies have poor prognosis since there are no effective standard treatments. Tumors associated with alterations in the SWI/SNF complex are generally infiltrated by a high number of TILs that have been able to recognize a tumor antigen. The use of those TILs as a therapeutic strategy is a promising immunotherapy approach. The TILTS study The TILTS study is a clinical trial designed to assess the activity of adoptive cell therapy with TILs in these tumor types. The TILTS study is a prospective, single-arm, multicenter Phase II study that uses personalized TILs treatment in advanced tumors associated with alterations in the SWI/SNF complex. The primary end point is ORR per RECIST v1.1 as assessed by investigator. Secondary end points include toxicity evaluation, PFS and OS, among others. In addition, an associated translational study will be conducted in order to better understand the biology of these malignancies and their relationship with the immune system. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

Author

Tamborero, David, Dienstmann, Rodrigo, Rachid, Maan Haj, Boekel, Jorrit, Lopez-Fernandez, Adria, Jonsson, Markus, Razzak, Ali, Braña, Irene, De Petris, Luigi, Yachnin, Jeffrey, Baird, Richard D., Loriot, Yohann, Massard, Christophe, Martin-Romano, Patricia, Opdam, Frans, Schlenk, Richard F., Vernieri, Claudio, Masucci, Michele, Villalobos, Xenia, Chavarria, Elena, Balmaña, Judith, Apolone, Giovanni, Caldas, Carlos, Bergh, Jonas, Ernberg, Ingemar, Fröhling, Stefan, Garralda, Elena, Karlsson, Claes, Tabernero, Josep, Voest, Emile, Rodon, Jordi, and Lehtiö, Janne

Published
2022
Full Text
View/download PDF

22. First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours

Author

Naing, Aung, primary, Papadopoulos, Kyriakos P, additional, Pishvaian, Michael J, additional, Rahma, Osama, additional, Hanna, Glenn J, additional, Garralda, Elena, additional, Saavedra, Omar, additional, Gogov, Sven, additional, Kallender, Howard, additional, Cheng, LuLu, additional, Smith, Michael, additional, Chen, Xuejun, additional, Kuriakose, Emil, additional, and Bauer, Todd, additional

Published
2024
Full Text
View/download PDF

23. Histology-informed liver diffusion MRI: biophysical model design and demonstration in cancer immunotherapy

Author

Grussu, Francesco, primary, Bernatowicz, Kinga, additional, Palombo, Marco, additional, Casanova-Salas, Irene, additional, Barba, Ignasi, additional, Simonetti, Sara, additional, Serna, Garazi, additional, Grigoriou, Athanasios, additional, Voronova, Anna, additional, Garay, Valezka, additional, Corral, Juan Francisco, additional, Vidorreta, Marta, additional, Garcia-Polo Garcia, Pablo, additional, Merino, Xavier, additional, Mast, Richard, additional, Roson, Nuria, additional, Escobar, Manuel, additional, Vieito, Maria, additional, Toledo, Rodrigo, additional, Nuciforo, Paolo, additional, Mateo, Joaquin, additional, Garralda, Elena, additional, and Perez-Lopez, Raquel, additional

Published
2024
Full Text
View/download PDF

24. Drug Cost Avoidance Resulting from Participation in Clinical Trials: A 10-Year Retrospective Analysis of Cancer Patients with Solid Tumors

Author

Carreras, Maria-Josep, primary, Renedo-Miró, Berta, additional, Valdivia, Carolina, additional, Tomás-Guillén, Elena, additional, Farriols, Anna, additional, Mañós, Laura, additional, Vidal, Jana, additional, Alcalde, María, additional, De la Paz, Isabel, additional, Jiménez-Lozano, Inés, additional, Palacio-Lacambra, Maria-Eugenia, additional, Sabaté, Nuria, additional, Felip, Enriqueta, additional, Garralda, Elena, additional, Garau, Margarita, additional, Gorgas, Maria-Queralt, additional, Monterde, Josep, additional, and Tabernero, Josep, additional

Published
2024
Full Text
View/download PDF

26. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

Author

Subbiah, Vivek, Hu, Mimi I, Wirth, Lori J, Schuler, Martin, Mansfield, Aaron S, Curigliano, Giuseppe, Brose, Marcia S, Zhu, Viola W, Leboulleux, Sophie, Bowles, Daniel W, Baik, Christina S, Adkins, Douglas, Keam, Bhumsuk, Matos, Ignacio, Garralda, Elena, Gainor, Justin F, Lopes, Gilberto, Lin, Chia-Chi, Godbert, Yann, Sarker, Debashis, Miller, Stephen G, Clifford, Corinne, Zhang, Hui, Turner, Christopher D, and Taylor, Matthew H

Published
2021
Full Text
View/download PDF

27. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

Author

Gainor, Justin F, Curigliano, Giuseppe, Kim, Dong-Wan, Lee, Dae Ho, Besse, Benjamin, Baik, Christina S, Doebele, Robert C, Cassier, Philippe A, Lopes, Gilberto, Tan, Daniel S W, Garralda, Elena, Paz-Ares, Luis G, Cho, Byoung Chul, Gadgeel, Shirish M, Thomas, Michael, Liu, Stephen V, Taylor, Matthew H, Mansfield, Aaron S, Zhu, Viola W, Clifford, Corinne, Zhang, Hui, Palmer, Michael, Green, Jennifer, Turner, Christopher D, and Subbiah, Vivek

Published
2021
Full Text
View/download PDF

29. High-throughput molecular assays for inclusion in personalised oncology trials – State-of-the-art and beyond

Author

Edsjö, Anders, Russnes, Hege G., Lehtiö, Janne, Tamborero, David, Hovig, Eivind, Stenzinger, Albrecht, Rosenquist, Richard, Janowska, Agnieszka, Rioja, Alba López, Razzak, Ali, Lepland, Anni, Marra, Antonio, Planken, Anu, Helland, Åslaug, Patocs, Attila, Mainoli, Beatrice, Ryll, Bettina, Brasiuniene, Birute, Kazdal, Daniel, Cerina, Dora, Hult, Ebba Hallersjö, Baltruškevičienė, Edita, Vrdoljak, Eduard, Chavarria, Elena, Garralda, Elena, Aas, Eline, Bjørgo, Elisa, Voest, Emile, Curigliano, Giuseppe, Fagereng, Gro Live, Gelderblom, Hans, Verheul, Henk, Timmer, Hans, Brana, Irene, Lugowska, Iwona, Blay, Jean Yves, Oliveira, Julio, Rekker, Kadri, Toome, Kadri, Jalkanen, Katriina, Taskén, Kjetil, Smeland, Knut, Ojamaa, Kristiina, Rohrberg, Kristoffer Staal, Verlingue, Loic, Antouly, Manon, Mustonen, Mika, Zagami, Paola, Nagy, Péter, Nygren, Peter, Asplund, Peter, Sabaliauskaite, Rasa, Henrique, Rui, van Waalwijk van Doorn-Khosrovani, Sahar Barjesteh, Brabrand, Sigmund, Ekman, Simon, Mohammad, Soemeya Haj, Jarmalaite, Sonata, Juslin, Tanja, Kahre, Tiina, Kringelbach, Tina, Guren, Tormod, Lassen, Ulrik, Grolmusz, Vince Kornél, Alberu, Xenia Villabour, Edsjö, Anders, Russnes, Hege G., Lehtiö, Janne, Tamborero, David, Hovig, Eivind, Stenzinger, Albrecht, Rosenquist, Richard, Janowska, Agnieszka, Rioja, Alba López, Razzak, Ali, Lepland, Anni, Marra, Antonio, Planken, Anu, Helland, Åslaug, Patocs, Attila, Mainoli, Beatrice, Ryll, Bettina, Brasiuniene, Birute, Kazdal, Daniel, Cerina, Dora, Hult, Ebba Hallersjö, Baltruškevičienė, Edita, Vrdoljak, Eduard, Chavarria, Elena, Garralda, Elena, Aas, Eline, Bjørgo, Elisa, Voest, Emile, Curigliano, Giuseppe, Fagereng, Gro Live, Gelderblom, Hans, Verheul, Henk, Timmer, Hans, Brana, Irene, Lugowska, Iwona, Blay, Jean Yves, Oliveira, Julio, Rekker, Kadri, Toome, Kadri, Jalkanen, Katriina, Taskén, Kjetil, Smeland, Knut, Ojamaa, Kristiina, Rohrberg, Kristoffer Staal, Verlingue, Loic, Antouly, Manon, Mustonen, Mika, Zagami, Paola, Nagy, Péter, Nygren, Peter, Asplund, Peter, Sabaliauskaite, Rasa, Henrique, Rui, van Waalwijk van Doorn-Khosrovani, Sahar Barjesteh, Brabrand, Sigmund, Ekman, Simon, Mohammad, Soemeya Haj, Jarmalaite, Sonata, Juslin, Tanja, Kahre, Tiina, Kringelbach, Tina, Guren, Tormod, Lassen, Ulrik, Grolmusz, Vince Kornél, and Alberu, Xenia Villabour

Abstract

In the last decades, the development of high-throughput molecular assays has revolutionised cancer diagnostics, paving the way for the concept of personalised cancer medicine. This progress has been driven by the introduction of such technologies through biomarker-driven oncology trials. In this review, strengths and limitations of various state-of-the-art sequencing technologies, including gene panel sequencing (DNA and RNA), whole-exome/whole-genome sequencing and whole-transcriptome sequencing, are explored, focusing on their ability to identify clinically relevant biomarkers with diagnostic, prognostic and/or predictive impact. This includes the need to assess complex biomarkers, for example microsatellite instability, tumour mutation burden and homologous recombination deficiency, to identify patients suitable for specific therapies, including immunotherapy. Furthermore, the crucial role of biomarker analysis and multidisciplinary molecular tumour boards in selecting patients for trial inclusion is discussed in relation to various trial concepts, including drug repurposing. Recognising that today's exploratory techniques will evolve into tomorrow's routine diagnostics and clinical study inclusion assays, the importance of emerging technologies for multimodal diagnostics, such as proteomics and in vivo drug sensitivity testing, is also discussed. In addition, key regulatory aspects and the importance of patient engagement in all phases of a clinical trial are described. Finally, we propose a set of recommendations for consideration when planning a new precision cancer medicine trial.image

Published
2024

32. Biomarker and pharmacodynamic activity of the transforming growth factor‐beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors

Author

Robbrecht, Debbie, primary, Grob, Jean‐Jacques, additional, Bechter, Oliver, additional, Simonelli, Matteo, additional, Doger, Bernard, additional, Borbath, Ivan, additional, Butler, Marcus O., additional, Cheng, Tina, additional, Romano, Patricia Martin, additional, Pons‐Tostivint, Elvire, additional, Di Nicola, Massimo, additional, Curigliano, Giuseppe, additional, Ryu, Min‐Hee, additional, Rodriguez‐Vida, Alejo, additional, Schadendorf, Dirk, additional, Garralda, Elena, additional, Abbadessa, Giovanni, additional, Demers, Brigitte, additional, Amrate, Amele, additional, Wang, Hong, additional, Lee, Joon Sang, additional, Pomponio, Robert, additional, and Wang, Rui, additional

Published
2024
Full Text
View/download PDF

33. Identification of Precise 3D CT Radiomics for Habitat Computation by Machine Learning in Cancer

Author

Prior, Olivia, primary, Macarro, Carlos, additional, Navarro, Víctor, additional, Monreal, Camilo, additional, Ligero, Marta, additional, Garcia-Ruiz, Alonso, additional, Serna, Garazi, additional, Simonetti, Sara, additional, Braña, Irene, additional, Vieito, Maria, additional, Escobar, Manuel, additional, Capdevila, Jaume, additional, Byrne, Annette T., additional, Dienstmann, Rodrigo, additional, Toledo, Rodrigo, additional, Nuciforo, Paolo, additional, Garralda, Elena, additional, Grussu, Francesco, additional, Bernatowicz, Kinga, additional, and Perez-Lopez, Raquel, additional

Published
2024
Full Text
View/download PDF

34. Updated efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion gastrointestinal (GI) cancer.

Author

Shen, Lin, primary, Andre, Thierry, additional, Chung, Hyun Cheol Cheol, additional, Deeken, John F., additional, Garralda, Elena, additional, Italiano, Antoine, additional, Leyvraz, Serge, additional, Liu, Tianshu, additional, Burcoveanu, Domnita-Ileana, additional, Grugel, Robin, additional, Mussi, Chiara E., additional, Xu, Rui-Hua, additional, Hong, David S., additional, Drilon, Alexander E., additional, and Berlin, Jordan, additional

Published
2024
Full Text
View/download PDF

35. FIGURE 4 from Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression

Author

Ligero, Marta, primary, Serna, Garazi, primary, El Nahhas, Omar S.M., primary, Sansano, Irene, primary, Mauchanski, Siarhei, primary, Viaplana, Cristina, primary, Calderaro, Julien, primary, Toledo, Rodrigo A., primary, Dienstmann, Rodrigo, primary, Vanguri, Rami S., primary, Sauter, Jennifer L., primary, Sanchez-Vega, Francisco, primary, Shah, Sohrab P., primary, Ramón y Cajal, Santiago, primary, Garralda, Elena, primary, Nuciforo, Paolo, primary, Perez-Lopez, Raquel, primary, and Kather, Jakob Nikolas, primary

Published
2024
Full Text
View/download PDF

36. Caring for patients with cancer in the COVID-19 era

Author

van de Haar, Joris, Hoes, Louisa R., Coles, Charlotte E., Seamon, Kenneth, Fröhling, Stefan, Jäger, Dirk, Valenza, Franco, de Braud, Filippo, De Petris, Luigi, Bergh, Jonas, Ernberg, Ingemar, Besse, Benjamin, Barlesi, Fabrice, Garralda, Elena, Piris-Giménez, Alejandro, Baumann, Michael, Apolone, Giovanni, Soria, Jean Charles, Tabernero, Josep, Caldas, Carlos, and Voest, Emile E.

Published
2020
Full Text
View/download PDF

37. Pharmacokinetics (PK) of Tiragolumab in First‐in‐Human Study in Patients with Mixed Solid Tumors (GO30103).

Author

Garralda, Elena, Oh, Do Youn, Italiano, Antoine, Bedard, Philippe L., Delord, Jean‐Pierre, Calvo, Emiliano, LoRusso, Patricia, Wainberg, Zev, Cervantes, Andres, Rodriguez‐Vida, Alejo, Shemesh, Colby S., Sane, Rucha, Mendus, Diana, Ding, Hao, Hendricks, Robert, Meng, Ray, Cho, Byoung Chul, Kim, Tae Won, and Wu, Benjamin

Subjects
*PATIENT safety, *RESEARCH funding, *ANTINEOPLASTIC agents, *CLINICAL trials, *DESCRIPTIVE statistics, *MONOCLONAL antibodies, *INTRAVENOUS therapy, *CANCER cells, *DRUG tolerance
Abstract

Tiragolumab is a first‐in‐class, fully human IgG1/kappa anti‐TIGIT monoclonal antibody that blocks the binding of TIGIT to CD155 (the poliovirus receptor). We summarize the pharmacokinetics (PK) data from the phase 1a/1b GO30103 study of Q3W (every 3 weeks) sequential dosing of tiragolumab (2, 8, 30, 100, 400, 600, or 1200 mg) followed by atezolizumab (1200 mg), Q4W (every 4 weeks) sequential dosing (tiragolumab 840 mg followed by atezolizumab 1680 mg), and Q4W co‐infusion (tiragolumab 840 mg plus atezolizumab 1680 mg). Serum samples were collected at multiple time points following tiragolumab and atezolizumab intravenous infusion in patients with solid tumors for PK and immunogenicity assessment. The serum PK profile of tiragolumab appeared to be biphasic, with a rapid distribution phase followed by a slower elimination phase when administered alone or in combination with atezolizumab. In phase 1a, across doses of tiragolumab ranging from 2 to 1200 mg (cycle 1), the geometric mean (GM), coefficient of variation (CV%), serum tiragolumab Cmax ranged from 0.682 to 270 µg/mL (18.6% to 36.5%) and Cmin ranged from 0.0125 to 75.3 µg/mL (0.0% to 24.2%). The GM systemic exposure (area under the plasma drug concentration‐time curve, AUC0‐21) ranged from 310 to 2670 µg day/mL (20.5% to 27.0%); interindividual variability in AUC0‐21 ranged from 20.5% to 43.9%. Tiragolumab exposure increased in an approximately dose‐proportional manner when administered alone or with atezolizumab at doses ≥100 mg. Postbaseline, 4/207 patients (1.9%) were positive for treatment‐emergent antidrug antibodies (ADA) against tiragolumab, each at a single time point. Tiragolumab combined with atezolizumab demonstrated desirable PK properties, with no drug‐drug interactions or immunogenicity liability. There were no meaningful differences in tiragolumab or atezolizumab exposure between the Q4W co‐infusion and sequential dosing cohorts. ClinicalTrials.gov: NCT02794571 (date of registration June 6, 2016). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. Weakly supervised deep learning predicts immunotherapy response in solid tumors based on PD-L1 expression

Author

Ligero, Marta, primary, Serna, Garazi, additional, El Nahhas, Omar S.M., additional, Sansano, Irene, additional, Mauchanski, Siarhei, additional, Viaplana, Cristina, additional, Calderaro, Julien, additional, Toledo, Rodrigo A, additional, Dienstmann, Rodrigo, additional, Vanguri, Rami S., additional, Sauter, Jennifer L., additional, Sanchez-Vega, Francisco, additional, Shah, Sohrab P, additional, Ramón y Cajal, Santiago, additional, Garralda, Elena, additional, Nuciforo, Paolo, additional, Perez-Lopez, Raquel, additional, and Kather, Jakob Nikolas, additional

Published
2023
Full Text
View/download PDF

39. A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies

Author

Lin, Chia-Chi, primary, Garralda, Elena, additional, Schöffski, Patrick, additional, Hong, David S., additional, Siu, Lillian L., additional, Martin, Miguel, additional, Maur, Michela, additional, Hui, Rina, additional, Soo, Ross A, additional, Chiu, Joanne, additional, Zhang, Tian, additional, Ma, Brigette, additional, Kyi, Chrisann, additional, Tan, Daniel SW, additional, Cassier, Philippe A., additional, Sarantopoulos, John, additional, Weickhardt, Andrew, additional, Carvajal, Richard D., additional, Spratlin, Jennifer, additional, Esaki, Taito, additional, Rolland, Fréderic, additional, Akerley, Wallace, additional, Deschler-Baier, Barbara, additional, Rispoli, Lawrence, additional, Samant, Tanay S., additional, Chowdhury, Niladri Roy, additional, Gusenleitner, Daniel, additional, Kwak, Eunice L., additional, Askoxylakis, Vasileios, additional, and De Braud, Filippo, additional

Published
2023
Full Text
View/download PDF

40. Pharmacokinetics (PK) of Tiragolumab in First‐in‐Human Study in Patients With Mixed Solid Tumors (GO30103)

Author

Garralda, Elena, primary, Oh, Do Youn, additional, Italiano, Antoine, additional, Bedard, Philippe L., additional, Delord, Jean‐Pierre, additional, Calvo, Emiliano, additional, LoRusso, Patricia, additional, Wainberg, Zev, additional, Cervantes, Andres, additional, Rodriguez‐Vida, Alejo, additional, Shemesh, Colby S., additional, Sane, Rucha, additional, Mendus, Diana, additional, Ding, Hao, additional, Hendricks, Robert, additional, Meng, Ray, additional, Cho, Byoung Chul, additional, Kim, Tae Won, additional, and Wu, Benjamin, additional

Published
2023
Full Text
View/download PDF

41. 728 A phase 1/2 study of JK08, an IL-15 antibody fusion protein targeting CTLA-4, in patients with advanced solid tumors

Author

Kotecki, Nuria, primary, Rottey, Sylvie, additional, Delafontaine, Brant, additional, Garralda, Elena, additional, Galvao, Vladimir, additional, Miguel, Maria de, additional, Saavedra, Omar, additional, Boni, Valentina, additional, McEwen, Amanda, additional, Singhal, Shalabh, additional, Murphy, Samuel L, additional, and Pandya, Naimish, additional

Published
2023
Full Text
View/download PDF

42. Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors

Author

Joerger, Markus, primary, Calvo, Emiliano, additional, Laubli, Heinz, additional, Lopez, Juanita, additional, Alonso, Guzmán, additional, Corral de la Fuente, Elena, additional, Hess, Dagmar, additional, König, David, additional, Sanchez Perez, Vicky, additional, Bucher, Christoph, additional, Jethwa, Sangeeta, additional, and Garralda, Elena, additional

Published
2023
Full Text
View/download PDF

43. Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

Author

Tamborero, David, Dienstmann, Rodrigo, Rachid, Maan Haj, Boekel, Jorrit, Lopez-Fernandez, Adria, Jonsson, Markus, Razzak, Ali, Braña, Irene, De Petris, Luigi, Yachnin, Jeffrey, Baird, Richard D., Loriot, Yohann, Massard, Christophe, Martin-Romano, Patricia, Opdam, Frans, Schlenk, Richard F., Vernieri, Claudio, Masucci, Michele, Villalobos, Xenia, Chavarria, Elena, Balmaña, Judith, Apolone, Giovanni, Caldas, Carlos, Bergh, Jonas, Ernberg, Ingemar, Fröhling, Stefan, Garralda, Elena, Karlsson, Claes, Tabernero, Josep, Voest, Emile, Rodon, Jordi, and Lehtiö, Janne

Published
2022
Full Text
View/download PDF

46. Supplementary Table S2 from Cellular Senescence Is Immunogenic and Promotes Antitumor Immunity

Author

Marin, Ines, primary, Boix, Olga, primary, Garcia-Garijo, Andrea, primary, Sirois, Isabelle, primary, Caballe, Adrià, primary, Zarzuela, Eduardo, primary, Ruano, Irene, primary, Attolini, Camille Stephan-Otto, primary, Prats, Neus, primary, López-Domínguez, José A, primary, Kovatcheva, Marta, primary, Garralda, Elena, primary, Muñoz, Javier, primary, Caron, Etienne, primary, Abad, María, primary, Gros, Alena, primary, Pietrocola, Federico, primary, and Serrano, Manuel, primary

Published
2023
Full Text
View/download PDF

47. Supplementary Fig. S4 from Cellular Senescence Is Immunogenic and Promotes Antitumor Immunity

Author

Marin, Ines, primary, Boix, Olga, primary, Garcia-Garijo, Andrea, primary, Sirois, Isabelle, primary, Caballe, Adrià, primary, Zarzuela, Eduardo, primary, Ruano, Irene, primary, Attolini, Camille Stephan-Otto, primary, Prats, Neus, primary, López-Domínguez, José A, primary, Kovatcheva, Marta, primary, Garralda, Elena, primary, Muñoz, Javier, primary, Caron, Etienne, primary, Abad, María, primary, Gros, Alena, primary, Pietrocola, Federico, primary, and Serrano, Manuel, primary

Published
2023
Full Text
View/download PDF

48. Data from Cellular Senescence Is Immunogenic and Promotes Antitumor Immunity

Author

Marin, Ines, primary, Boix, Olga, primary, Garcia-Garijo, Andrea, primary, Sirois, Isabelle, primary, Caballe, Adrià, primary, Zarzuela, Eduardo, primary, Ruano, Irene, primary, Attolini, Camille Stephan-Otto, primary, Prats, Neus, primary, López-Domínguez, José A, primary, Kovatcheva, Marta, primary, Garralda, Elena, primary, Muñoz, Javier, primary, Caron, Etienne, primary, Abad, María, primary, Gros, Alena, primary, Pietrocola, Federico, primary, and Serrano, Manuel, primary

Published
2023
Full Text
View/download PDF

49. Mean plasma SRA737 concentration over time from A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer

Author

Jones, Robert, primary, Plummer, Ruth, primary, Moreno, Victor, primary, Carter, Louise, primary, Roda, Desamparados, primary, Garralda, Elena, primary, Kristeleit, Rebecca, primary, Sarker, Debashis, primary, Arkenau, Tobias, primary, Roxburgh, Patricia, primary, Walter, Harriet S., primary, Blagden, Sarah, primary, Anthoney, Alan, primary, Klencke, Barbara J., primary, Kowalski, Mark M., primary, and Banerji, Udai, primary

Published
2023
Full Text
View/download PDF

50. Mean exposure (AUC0–12) by dose level from A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer

Author

Jones, Robert, primary, Plummer, Ruth, primary, Moreno, Victor, primary, Carter, Louise, primary, Roda, Desamparados, primary, Garralda, Elena, primary, Kristeleit, Rebecca, primary, Sarker, Debashis, primary, Arkenau, Tobias, primary, Roxburgh, Patricia, primary, Walter, Harriet S., primary, Blagden, Sarah, primary, Anthoney, Alan, primary, Klencke, Barbara J., primary, Kowalski, Mark M., primary, and Banerji, Udai, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results